Chi Leung Chiang, Clinical Associate Professor at The University of Hong Kong, LKS Faculty of Medicine, shared a post on LinkedIn about a paper he co-authored with colleagues published in the International Journal of Radiation Oncology, Biology, Physics:
“Post-hoc analysis of START-FIT
First prospective series to demonstrate that SBRT could induce contralateral lobe hypertrophy in HCC
- Around a 30% increase in future liver remnant (FLR)
- Fastest rate of hypertrophy in the first 3 months
- Ongoing hypertrophy until plateauing at 12 months
Implications:
- Further support START-FIT as a promising conversion therapy of uHCC
- In many institutions around the world, Y90 radioembolization is often preferred over SBRT to treat HCC because it can both shrink the primary tumour and induce contralateral lobe hypertrophy. Our data strengthen the rationale of using SBRT in locally advanced HCC.”
Title: Compensatory Hypertrophy and Changes of Liver Function after Sequential TACE, SBRT, and Immunotherapy (START-FIT) in Unresectable Hepatocellular Carcinoma
Authors: Ryo Wan Lung Yeung, Keith Wan Hang Chiu, Kenneth Sik Kwan Chan, Natalie Sean Man Wong, Wenqi Chen, Venus Wan Yan Lee, Francis Ann Shing Lee, Albert Chi Yan Chan, and Chi Leung Chiang
You can read the Full Article in the International Journal of Radiation Oncology, Biology, Physics.
More posts featuring Chi Leung Chiang.
